Literature DB >> 29188418

Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery.

Stephanie J Blocker1, Anthony F Shields2,3.   

Abstract

Molecular imaging is a vital tool to non-invasively measure nanoparticle delivery to solid tumors. Despite the myriad of nanoparticles studied for cancer, successful applications of nanoparticles in humans is limited by inconsistent and ineffective delivery. Successful nanoparticle delivery in preclinical models is often attributed to enhanced permeability and retention (EPR)-a set of conditions that is heterogeneous and transient in patients. Thus, researchers are evaluating therapeutic strategies to modify nanoparticle delivery, particularly treatments which have demonstrated effects on EPR conditions. Imaging nanoparticle distribution provides a means to measure the effects of therapeutic intervention on nanoparticle delivery to solid tumors. This review focuses on the utility of imaging to measure treatment-induced changes in nanoparticle delivery to tumors and provides preclinical examples studying a broad range of therapeutic interventions.

Entities:  

Keywords:  Chemotherapy; Imaging; Nanoparticles; Theranostics

Mesh:

Year:  2018        PMID: 29188418      PMCID: PMC6836466          DOI: 10.1007/s11307-017-1142-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  74 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas.

Authors:  M L Matteucci; G Anyarambhatla; G Rosner; C Azuma; P E Fisher; M W Dewhirst; D Needham; D E Thrall
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

4.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

Authors:  Kazuya Nakamura; Amr S Abu Lila; Mariko Matsunaga; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

6.  Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Authors:  Elena Geretti; Shannon Curtis Leonard; Nancy Dumont; Helen Lee; Jinzi Zheng; Raquel De Souza; Daniel F Gaddy; Christopher W Espelin; David A Jaffray; Victor Moyo; Ulrik B Nielsen; Thomas J Wickham; Bart S Hendriks
Journal:  Mol Cancer Ther       Date:  2015-07-10       Impact factor: 6.261

7.  Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts.

Authors:  Xiangpeng Zheng; Beth A Goins; Ivan L Cameron; Cristina Santoyo; Ande Bao; Victoria C Frohlich; Gary D Fullerton
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

Review 8.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

9.  Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.

Authors:  Yongmei Zhao; Zachary H Houston; Joshua D Simpson; Liyu Chen; Nicholas L Fletcher; Adrian V Fuchs; Idriss Blakey; Kristofer J Thurecht
Journal:  Mol Pharm       Date:  2017-09-07       Impact factor: 4.939

10.  Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.

Authors:  Bonnie L Hylander; Arindam Sen; Sarah H Beachy; Rose Pitoniak; Soumya Ullas; John F Gibbs; Jingxin Qiu; Joshua D Prey; Gerald J Fetterly; Elizabeth A Repasky
Journal:  J Control Release       Date:  2015-09-03       Impact factor: 9.776

View more
  3 in total

1.  ES-MION-Based Dual-Modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging.

Authors:  Xiuyan Wei; Haitao Zhao; Gang Huang; Jianhua Liu; Weina He; Qingqing Huang
Journal:  ACS Omega       Date:  2022-01-18

Review 2.  Intravenously Infused Stem Cells for Cancer Treatment.

Authors:  Alison R Mercer-Smith; Ingrid A Findlay; Hunter N Bomba; Shawn D Hingtgen
Journal:  Stem Cell Rev Rep       Date:  2021-06-17       Impact factor: 5.739

Review 3.  Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.

Authors:  Josanne Sophia de Maar; Alexandros Marios Sofias; Tiffany Porta Siegel; Rob J Vreeken; Chrit Moonen; Clemens Bos; Roel Deckers
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.